No abstract

Summary Background: The relationship between haptoglobin polymorphism and oxidative stress in hemodialysis patients is not fully understood. In this study, total antioxidant capacity and ce ru - loplasmin ferroxidase activity were evaluated in relation to haptoglobin phenotype distribution in hemodialysis patients. Methods: Serum samples collected from 161 patients and 84 healthy controls were haptoglobin-typed by electrophoresis. Ceruloplasmin ferroxidase activity and total antioxidant capacity were assayed using colorimetric methods. Results: Irrespective of the haptoglobin phenotype, patients exhibited significantly lower total antioxidant capacity (1.42± 0.29 vs. 1.55±0.28 mmol/L, P=0.002) and higher ferroxidase activity than controls. Frequency of Hp1-1 and Hp2-1 in patients was 15.5% and 36% as compared with 9.5% and 41.7% in controls. While ferroxidase activity was lower in Hp2-2 patients than in controls (142±61 vs. 179±47 U/L, P=0.002), it was higher in Hp2-1 (173±56 U/L) and Hp1-1 (170±54 U/L) patients than in controls (141±43 and 99±30 U/L respectively) (P=0.002 and 0.009). Ferroxidase activity in Hp2-2 patients was significantly lower than that of Hp2-1 or Hp1-1 patients (P=0.004 and 0.034). Total antioxidant capacity was significantly lower only in Hp2-2 patients (1.44±0.25) compared to that in Hp2-2 controls (1.65±0.22) (P=0.000). Conclusions:These findings suggest that haptoglobin polymorphism can differentially impact oxidative stress levels in hemodialysis patients.

No abstract

Growth differentiation factor (GDF)-15 was identified as a factor secreted by activated macrophages which plays an important role in cell growth, signal transduction, and apoptosis regulation . The aim of this study is to: Correlate serum level of growth differentiation factor 15(GDF-15) with disease activity and severity parameters in rheumatoid arthritis patient. This study will include thirty rheumatoid arthritis (RA) patients fulfilling the American College of Rheumatology/European League Against stiffness (ACR/EULAR) criteria to the analysis from claiming RA recruited from Rheumatology, restoration physical and drug outpatient facility What's more inpatient division about Benha school doctor's facilities. Also, twenty solid persons sex Also agdistis matched of the patients were selected in this study as An control bunch. Every last one of patients and controls were subjected with full history taking, full clinical examination, research center investigations that included cbc ,ESR. Crp. Rf , serum -Growth diferentation variable 15(GDF15) levels, those malady movement score -28 (DAS28)was used to assess the infection movement for rheumatiod joint inflammation. The wellbeing evaluation quaestionnaire (HAQ) might have been used to assess those utilitarian status. Those level of joint harm might have been evaluated as stated by Larsen strategy. Clinched alongside our ponder GDF15 levels were fundamentally higher to rheumatiod joint inflammation patients The point when contrasted with those control (p<0. 05). Accordig to pearsons corrrelation ,serum GDF15 levels were postivitly associated with esr level,morning firmness. DAS28 score. Youthful joint. Swollen joint,and x beam "around body of evidence one assembly. GDF15 might assume a part in the pathway from claiming infection action. Joint inclusion large amounts from claiming GDF-15 were connected with sickness activity, level of ESR, morning stiffness, delicate joint count,.

Women are more likely than men to die from cancer if they have breast cancer (BC). It was triggered by a slew of risk factors. Breast cancer patients have a better prognosis if they are diagnosed early. Recent research has shown that microRNAs may play an important role in the early detection and prognosis of breast cancer. There are approximately 23 nucleotides in microRNAs, making them tiny uncoding RNAs. Breast cancer development may be slowed or halted through the control of cell proliferation and death by miRNAs. expression was examined in BC females to see whether it was associated with the disease's stage and to determine if miRNA-329 might be used in the diagnosis of BC.